Place an Order

References From Results Page

†Study:

  1. de Leon JM, Driver VR, Fylling CP, et al. The clinical relevance of treating chronic wounds with an enhanced near-physiological concentration of platelet-rich plasma gel. Adv Skin Wound Care. 2011; 24(8): 357–368.

††Study:

  1. Driver VR, Hanft J, Fylling CP, Beriou JM, AutoloGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ost Wound Manage. 2006; 52(6): 68–87.

††† Multiple Studies:

  1. Driver VR, Hanft J, Fylling CP, Beriou JM, AutoloGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers Ostomy Wound Manage. 2006; 52(6): 68–87.
  2. Osiris FORM 10-Q for the quarterly period ended September 30, 2013.
  3. Veves A, Falanga V, Armstrong DG, Sabolinski, ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers. Diabetes Care. 2001; 24(2): 290–295.
  4. Steed DL, Study Group DU. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic foot ulcers. J of Vasc Surg. 1995; 21(1): 71-81.
  5. Marston WA, Hanft J, Norwood P, et al. The efficacy and safety of dermagraft in improving the healing of chronic diabetic foot ulcers.. Diabetes Care. 2003; 26: 1701–1705.

 

AURIX/AUTOLOGEL CLINICAL CASE STUDY PUBLICATIONS

Prospective, Randomized, Blinded, Multi-Center, Controlled Trial

  1. Driver VR, Hanft J, Fylling CP, Beriou JM, AutoloGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet- rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2006; 52(6): 68–87.

Comparison Studies: Run In Treatment vs AutoloGel Treatment

  1. Carter M, Fylling C, Li W, et al. A statistical analysis of a wound outcomes registry using run-in data: clinical impact of platelet rich plasma gel on healing trajectory. Wound J. 2011; 8: 638–650.
  2. Sakata J, Sasaki S, Handa K, et al. A retrospective, longitudinal study to evaluate healing lower extremity wounds in patients with diabetes mellitus and ischemia using standard protocols of care and platelet-rich plasma gel in a Japanese wound care program. Ostomy Wound Manage. 2012; 58(4): 36–49.

Observational Studies (de Leon Article Includes Comparative Analysis)

  1. Frykberg RG, Driver VR, Carman D, et al. Chronic wounds treated with a physiologically relevant concentration of platelet- rich plasma gel: a prospective case series. Ostomy Wound Manage. 2010; 56(6): 36–44.
  2. Rappl LM. Effect of platelet rich plasma gel in a physiologically relevant platelet concentration on wounds in persons with spinal cord injury. Wound J. 2011; 8(2): 187–195.
  3. de Leon J, Driver VR, Fylling CP, et al. The clinical relevance of treating chronic wounds with an enhanced near-physiological concentration of platelet rich plasma gel. Adv Skin Wound Care. 2011; 24(8): 357–368.

Case Series

  1. Gurvich L. Synergism in using negative pressure wound therapy with alternated applications of autologous platelet-derived growth factors in treating post-acute surgical wounds. Wounds – A Compendium Clin. Res. Pract. 2009; 21(5): 134–140.

Cost Effectiveness

  1. Dougherty EJ. An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers. Adv Skin Wound Care. 2008; 21(12): 568–75.

Systematic Review of PRP Literature Which Includes AutoloGel PRP Gel

  1. Carter, MJ, Fylling, CP, Parnell, LKS. Use of platelet rich plasma gel on wound healing: a systematic review and meta-analysis. ePlasty. 2011; 11: 382-406.

Let’s Connect